Evidence map›Paper›PMID 38873038›Full record

ReviewExperimental and therapeutic medicine2024

Potential clinical applications of current and future oral forms of desmopressin (Review).

Karel Everaert, Tove Holm-Larsen, George Bou Kheir, Sylvie Rottey, Jeffrey P Weiss, Johan Vande Walle, Abdo E Kabarriti, Lien Dossche, François Hervé, Anne-Françoise Spinoit and 2 more

Abstract readReview
In one paragraph

Review in Experimental and therapeutic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Karel EveraertFaculty of Medicine and Health Sciences, Department of Human Structure and Repair, Ghent University Hospital, 9000 Ghent, Belgium.
Tove Holm-LarsenFaculty of Medicine and Health Sciences, Department of Human Structure and Repair, Ghent University Hospital, 9000 Ghent, Belgium.
George Bou KheirDepartment of Urology, Ghent University Hospital, 9000 Ghent, Belgium.
Sylvie RotteyDrug Research Unit and Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
Jeffrey P WeissDepartment of Urology, State University of New York Downstate Health Sciences University, New York City, NY 11203, USA.
Johan Vande WalleDepartment of Pediatric Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.
Abdo E KabarritiDepartment of Urology, State University of New York Downstate Health Sciences University, New York City, NY 11203, USA.
Lien DosscheFaculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Ghent University Hospital, 9000 Ghent, Belgium.
François HervéDepartment of Urology, Ghent University Hospital, 9000 Ghent, Belgium.
Anne-Françoise SpinoitDepartment of Pediatric & Reconstructive Urology, Ghent University Hospital, 9000 Ghent, Belgium.
Jens Peter NørgaardResearch & Development, Ferring Pharmaceuticals A/S, Ferring International PharmaScience Center, 2770 Copenhagen, Denmark.
Kristian Vinter JuulResearch & Development, Ferring Pharmaceuticals A/S, Ferring International PharmaScience Center, 2770 Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmopressin is a synthetic analogue of vasopressin and a selective vasopressin receptor 2 agonist. It was first synthesised in 1967 and utilised for its antidiuretic properties. It is also used in bleeding disorders to enhance clotting. Other potential uses of the drug have been reported. The present review aims to provide a broad overview of the literature on potential further uses of oral forms of desmopressin. Key therapeutic areas of interest were identified based on known physiological activities/targets of desmopressin or reports of an effect of desmopressin in the literature. The feasibility of adequate dosing with oral forms of the drug was also considered. Systematic literature searches were carried out using the silvi.ai software for the identified areas, and summaries of available papers were included in tables and discussed. The results of the searches showed that desmopressin has been investigated for its efficacy in a number of areas, including bleeding control, renal colic, the central nervous system and oncology. Evidence suggests that oral desmopressin may have the potential to be of clinical benefit for renal colic and bleeding control in particular. However, further research is needed to clarify its effect in these areas, including randomised controlled studies and studies specifically of oral formulations (and doses). Further research may also yield findings for cancer, cognition and overactive bladder.

Indexed as

bleeding controldesmopressinoral formulationrenal colic

Identifiers

PMID38873038
PMCPMC11170333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.